Interview with Amy E. Cyr, MD, FACS: Identification and Management for High-Risk Women

Interview with Ashley Frith, MD: Metastatic Disease Research Highlights from the 2025 San Antonio Breast Cancer Symposium

Interview with Ashley Frith, MD: Early-Stage Disease Research Highlights from the 2025 San Antonio Breast Cancer Symposium

View all

Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.

For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.

Katie Newlin, Katie Newlin, RN, MSN, AGPCNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Lisa Salem, MSN, FNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

Real-world Risk of Recurrence by Nodal Status in Patients with HR+, HER2-, Node-positive, High-Risk Early Breast Cancer

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)

Evidence-Based Approaches for the Management of Side-Effects of Adjuvant Endocrine Therapy in Patients with Breast Cancer

Transgender Breast Cancer Screening

JAMA

Risk-based vs annual breast cancer screening: The WISDOM randomized clinical trial

Cancer Treatment Reviews

Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review

The American Surgeon

Assessing nodal positivity in men 70 years of age and older with clinically node negative hormone-receptor positive breast cancer to guide axillary intervention

The Breast

Genomic landscape of metastatic breast cancers in young adults: A liquid biopsy analysis of women aged 20-40 years

ESMO Open

A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: The RibOB study

Clinical Cancer Research

Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer open access

Clinical Cancer Research

The prognostic and predictive impact of ctDNA levels in patients with advanced breast cancer enrolled on the plasmaMATCH trial

Clinical Cancer Research

Real-world outcomes of elacestrant in ER+, HER2−, ESR1-mutant metastatic breast cancer

Future Oncology

OPERA-01: A phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy

Cancers

The prognostic and predictive value of body mass index in patients with HR+/HER2- breast cancer treated with CDK4/6 inhibitors: A systematic literature review

HR+ HER2- Breast Cancer Resource Center

Interview with Amy E. Cyr, MD, FACS: Identification and Management for High-Risk Women

Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

Real-world Risk of Recurrence by Nodal Status in Patients with HR+, HER2-, Node-positive, High-Risk Early Breast Cancer

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)

Evidence-Based Approaches for the Management of Side-Effects of Adjuvant Endocrine Therapy in Patients with Breast Cancer

Transgender Breast Cancer Screening

JAMA

Risk-based vs annual breast cancer screening: The WISDOM randomized clinical trial

Cancer Treatment Reviews

Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review

The American Surgeon

Assessing nodal positivity in men 70 years of age and older with clinically node negative hormone-receptor positive breast cancer to guide axillary intervention

The Breast

Genomic landscape of metastatic breast cancers in young adults: A liquid biopsy analysis of women aged 20-40 years

ESMO Open

A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: The RibOB study

Clinical Cancer Research

Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer open access

Clinical Cancer Research

The prognostic and predictive impact of ctDNA levels in patients with advanced breast cancer enrolled on the plasmaMATCH trial

Clinical Cancer Research

Real-world outcomes of elacestrant in ER+, HER2−, ESR1-mutant metastatic breast cancer

Future Oncology

OPERA-01: A phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy

Cancers

The prognostic and predictive value of body mass index in patients with HR+/HER2- breast cancer treated with CDK4/6 inhibitors: A systematic literature review

Navigating Treatment Adherence in Early-Stage Breast Cancer

Isolated Brain Metastasis in BRCA2-Mutated HR+ HER2- Breast Cancer

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer